http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Fenghu Li,Fan Mei,Shuishui Yin,Yanjun Du,Lili Hu,Wei Hong,Jiehui Li 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.1
Objective: To compare the efficacy and safety of neoadjuvant chemotherapy combined withconcurrent chemoradiotherapy (NACT+CCRT) vs. concurrent chemoradiotherapy (CCRT) inlocally advanced cer vical cancer (LACC) patients with large tumor masses. Methods: LACC patients with localized tumor diameter >4 cm, were randomly allocated in anunblinded 1:1 ratio to NACT+CCRT or CCRT groups. Patients in the NACT+CCRT group weregiven paclitaxel combined with cisplatin (TP) NACT ever y 3 weeks for 2 cycles, followed byCCRT, with the chemotherapy regimen the same as for NACT. CCRT group were given CCRTwith the same as for NACT. Results: From March 1, 2019, to June 30, 2021, 146 patients were included in the finalanalysis. Sixty-eight (93.2%) patients in the NACT+CCRT group and 66 (90.4%) patientsin the CCRT group completed the expected treatment course. The complete response (CR)rate in the NACT+CCRT group was significantly higher than in the CCRT group (87.7% vs. 67.6%, χ2=54.540, p=0.000). In the NACT+CCRT group, the 1- and 2-year overall sur vival(OS) rates were significantly higher than those in the CCRT group (96% vs. 89% and 89%vs. 79%, χ2=5.737, p=0.017). Additionally, the rate of recurrences and distant metastaseswas significantly lower in the NACT+CCRT group than in the CCRT group (4.11% vs. 7.35%,χ 2=4.059, p=0.021). Most treatment-related adverse events in both groups were grade 3. Conclusion: Compared to CCRT, NACT+CCRT might improve the treatment completionrate, increase CR rate and 1- and 2-year OS rates, and reduce distant metastases rate for LACCpatients with large tumor masses.